What Teriparatide is
Teriparatide is a parathyroid hormone fragment analog that activates PTH receptor signaling in approved bone-health contexts.
Teriparatide is grouped under Approved / Clinical on PeptideFactCheck because it is a strong example of a peptide fragment becoming a targeted medicine.
The useful starting point is to separate the molecule itself from the internet story around it. It is a peptide fragment drug with a clear osteoanabolic story.
Why people keep looking it up
People associate teriparatide with bone building.
Teriparatide is a PTH fragment analog that activates bone remodeling pathways in approved contexts.
Teriparatide tends to stay in the conversation because it touches a familiar public theme: pth receptor, bone formation, and osteoanabolic. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
The approved use is specific; bone-active peptide biology is not casual self-optimization.
Human trials and official labels support specific approved uses.
Mechanism follows PTH receptor activity and bone remodeling biology.
Why this page carries the current tier: Approved peptide analog with official labeling and human evidence.
The current seed trail for Teriparatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Risk discussion should use current official labels, especially because bone-active endocrine signaling is consequential.
FDA-approved teriparatide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Teriparatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Teriparatide is CID 16133850. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16133850
- Formula
- C181H291N55O51S2
- Molecular weight
- 4118
- InChIKey
- OGBMKVWORPGQRR-UMXFMPSGSA-N
Matched synonyms include TERIPARATIDE, 52232-67-4, Teriparatida, Teriparatidum, 1-34-Human PTH, Human PTH (1-34), ZT-034, LY 333334.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Teriparatide returns 181 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Teriparatide returns 4948 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- teriparatide
- Generic names
- TERIPARATIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA211939
Indications and usage. 1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebra...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Osteosarcoma : Avoid use in patients with increased risk of osteosarcoma including patients with open epiphyses, metabolic bone diseases including Paget's disease, bone metastases or history of skeletal malignancies, prior external beam or implant radiation therapy involving the skeleton, and hereditary disorders predisposing to osteosarcoma. ( 5.1 ) Hypercalcemia and Cutaneous Calcificati...
Contraindications. 4 CONTRAINDICATIONS Teriparatide injection is contraindicated in patients with hypersensitivity to teriparatide or to any of its excipients. Hypersensitivity reactions have included angioedema and anaphylaxis [see Adverse Reactions ( 6.2 )] . Patients with hypersensitivity to teriparatide or to any of its excipients ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.